Role of Advanced Glycation End Products in Hypertension and Atherosclerosis: Therapeutic Implications

被引:0
作者
Sudesh Vasdev
Vicki Gill
Pawan Singal
机构
[1] Memorial University of Newfoundland,Discipline of Medicine, Faculty of Medicine, Room H
[2] University of Manitoba,4310, Health Sciences Centre
来源
Cell Biochemistry and Biophysics | 2007年 / 49卷
关键词
Hypertension; Atherosclerosis; Advanced glycation end products; Insulin resistance; Oxidative stress; Inflammation;
D O I
暂无
中图分类号
学科分类号
摘要
The vascular diseases, hypertension and atherosclerosis, affect millions of individuals worldwide, and account for a large number of deaths globally. A better understanding of the mechanism of these conditions will lead to more specific and effective therapies. Hypertension and atherosclerosis are both characterized by insulin resistance, and we suggest that this plays a major role in their etiology. The cause of insulin resistance is not known, but may be a result of a combination of genetic and lifestyle factors. In insulin resistance, alterations in glucose and lipid metabolism lead to the production of excess aldehydes including glyoxal and methylglyoxal. These aldehydes react non-enzymatically with free amino and sulfhydryl groups of amino acids of proteins to form stable conjugates called advanced glycation end products (AGEs). AGEs act directly, as well as via receptors to alter the function of many intra- and extracellular proteins including antioxidant and metabolic enzymes, calcium channels, lipoproteins, and transcriptional and structural proteins. This results in endothelial dysfunction, inflammation and oxidative stress. All these changes are characteristic of hypertension and atherosclerosis. Human and animal studies have demonstrated that increased AGEs are also associated with these conditions. A pathological role for AGEs is substantiated by studies showing that therapies that attenuate insulin resistance and/or lower AGEs, are effective in decreasing oxidative stress, lowering blood pressure, and attenuating atherosclerotic vascular changes. These interventions include lipoic acid and other antioxidants, AGE breakers or soluble receptors of AGEs, and aldehyde-binding agents like cysteine. Such therapies may offer alternative specific means to treat hypertension and atherosclerosis. An adjunct therapy may be to implement lifestyle changes such as weight reduction, regular exercise, smoking cessation, and increasing dietary intake of fruits and vegetables that also decrease insulin resistance as well as oxidative stress.
引用
收藏
页码:48 / 63
页数:15
相关论文
共 50 条
  • [21] Aging ovary and the role for advanced glycation end products
    Pertynska-Marczewska, Magdalena
    Diamanti-Kandarakis, Evanthia
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2017, 24 (03): : 345 - 351
  • [22] Role of advanced glycation end products in cellular signaling
    Ott, Christiane
    Jacobs, Kathleen
    Haucke, Elisa
    Santos, Anne Navarrete
    Grune, Tilman
    Simm, Andreas
    [J]. REDOX BIOLOGY, 2014, 2 : 411 - 429
  • [23] The role of inflammaging and advanced glycation end products on paratonia in patients with dementia
    Drenth, Hans
    Zuidema, Sytse
    Bautmans, Ivan
    Hobbelen, Hans
    [J]. EXPERIMENTAL GERONTOLOGY, 2020, 142
  • [24] Role of advanced glycation end products and insulin resistance in diabetic nephropathy
    Parwani, Kirti
    Mandal, Palash
    [J]. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY, 2023, 129 (01) : 95 - 107
  • [25] Dietary Advanced Glycation End Products: Their Role in the Insulin Resistance of Aging
    Portero-Otin, Manuel
    de la Maza, M. Pia
    Uribarri, Jaime
    [J]. CELLS, 2023, 12 (13)
  • [26] Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes
    Yamagishi, Sho-ichi
    Matsui, Takanori
    Nakamura, Kazuo
    [J]. CURRENT DRUG TARGETS, 2007, 8 (10) : 1138 - 1143
  • [27] Contribution of dietary advanced glycation end products (AGE) to circulating AGE: role of dietary fat
    Davis, Kathleen E.
    Prasad, Chandan
    Vijayagopal, Parakat
    Juma, Shanil
    Adams-Huet, Beverley
    Imrhan, Victorine
    [J]. BRITISH JOURNAL OF NUTRITION, 2015, 114 (11) : 1797 - 1806
  • [28] Advanced glycation end products and insulin resistance
    Unoki, Hiroyuki
    Yamagishi, Sho-ichi
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (10) : 987 - 989
  • [29] Advanced glycation end products in clinical nephrology
    Kalousová, M
    Zima, T
    Tesar, V
    Stípek, S
    Sulková, S
    [J]. KIDNEY & BLOOD PRESSURE RESEARCH, 2004, 27 (01) : 18 - 28
  • [30] Advanced Glycation End Products and Diabetic Complications
    Singh, Varun Parkash
    Bali, Anjana
    Singh, Nirmal
    Jaggi, Amteshwar Singh
    [J]. KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2014, 18 (01) : 1 - 14